SNY - Sanofi

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
46.21
-0.25 (-0.54%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close46.46
Open45.95
Bid46.60 x 800
Ask46.63 x 1200
Day's Range45.90 - 46.22
52 Week Range40.00 - 46.60
Volume1,730,729
Avg. Volume1,366,092
Market Cap115.751B
Beta (3Y Monthly)0.40
PE Ratio (TTM)23.82
EPS (TTM)1.94
Earnings DateN/A
Forward Dividend & Yield1.74 (3.74%)
Ex-Dividend Date2019-05-07
1y Target Est52.00
Trade prices are not sourced from all markets
  • Top Trending: Abbott and Sanofi team up to help diabetes patients, Boeing’s board expected to reconsider engineering
    Yahoo Finance Video

    Top Trending: Abbott and Sanofi team up to help diabetes patients, Boeing’s board expected to reconsider engineering

    Top Trending: Abbott and Sanofi team up to help diabetes patients, Boeing’s board expected to reconsider engineering, and NBA's Raptors to introduce sports hijab for women.

  • Regeneron/Sanofi Gets Positive CHMP Opinion for Dupixent
    Zacks

    Regeneron/Sanofi Gets Positive CHMP Opinion for Dupixent

    Regeneron (REGN) and Sanofi get positive CHMP recommendation for the label expansion of asthma drug Dupixent in an additional indication.

  • Barrons.com

    Sanofi and Regeneron Stocks Will Gain Because Dupixent Collaboration is Big, Analysts Say

    Guggenheim analysts upgraded both Sanofi and Regeneron in part because of optimism about an antibody drug that treats a range of diseases on which the two companies have collaborated.

  • Sanofi (SNY) Soars to 52-Week High, Time to Cash Out?
    Zacks

    Sanofi (SNY) Soars to 52-Week High, Time to Cash Out?

    Sanofi (SNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

  • Business Wire

    Hagens Berman Files Second Class-Action Lawsuit Regarding Concealed Zantac Cancer Risk

    Class-action law firm Hagens Berman has filed a second lawsuit regarding Sanofi and Boehringer Ingelheim’s intentionally concealed cancer risks in its popular heartburn medication, Zantac. Attorneys are also calling the Food and Drug Administration’s consumer-facing recommendations regarding the instance of a carcinogenic chemical in Zantac “highly questionable,” and are urging those who take Zantac to consult with their doctors before continuing to take the medicine.

  • Stocks Reverse Lower On Trade Fears, But Small Caps Lose Less
    Investor's Business Daily

    Stocks Reverse Lower On Trade Fears, But Small Caps Lose Less

    Stock indexes reversed lower Friday afternoon, as the market for a second straight day seemed unable to hold early advances. The S&P; 500 today and other indexes fell sharply at 1:15 p.m. ET.

  • Bloomberg

    Carcinogen in Zantac Leads to Another Shipment Halt, Recall

    (Bloomberg) -- A global effort to remove gastrointestinal medication tainted with a potential carcinogen from the market gained momentum, as one of India’s largest generic drugmakers halted shipments to customers worldwide and Italy ordered a recall of some medicine that originated in India.Dr. Reddy’s Laboratories Ltd. said it is suspending all distribution of its ranitidine, the generic version of the Sanofi stomach drug Zantac, as a precautionary measure. The company expects “to provide an update in the coming days,” said spokeswoman Lori McCreary in an email.Separately, the Italian Drug Agency said in a statement it was ordering a recall of all versions of Zantac with active ingredient made by the India-based firm Saraca Laboratories Ltd. Italian regulators also banned the use of some types of Zantac produced by other pharmaceutical companies pending analysis of the drugs.U.S. and European Union regulators said last week they were investigating the discovery of the carcinogen NDMA, or N-Nitrosodimethylamine, in branded and generic Zantac. The regulators said they hadn’t ascertained how the drugs came to be contaminated. In the U.S., the Food and Drug Administration has so far left the drugs on the market.NDMA was also detected in a commonly prescribed class of blood-pressure drugs, leading to the recall of millions of pills in 30 countries beginning in July of last year. In addition to the Italian drug agency, Germany’s drug regulator indicated earlier this week there were wider recalls of ranitidine made with active ingredient from Saraca in Europe. Saraca supplies larger drugmakers that make the pills sold to patients.Health officials in Canada have asked all makers of ranitidine to stop distribution of the heartburn treatment in that country.Novartis AG’s generic-drug unit, Sandoz, halted global distribution on Wednesday of its generic Zantac, known as ranitidine. Brand-name Zantac maker Sanofi hasn’t halted distribution of the drug or any of its other ranitidine products outside of Canada. About two dozen generic drugmakers are FDA-approved to sell their own versions of prescription and over-the-counter Zantac in the U.S., including Sandoz and Dr. Reddy’sBloomberg News has reported on how poor quality controls and efforts to conceal manufacturing problems from the FDA have complicated oversight of overseas drug producers.As regulators deal with the Zantac investigation, the worldwide recall of tainted blood-pressure pills known as angiotensin II receptor blockers, or ARBs, is still widening. On Thursday, India-based Torrent Pharmaceuticals Ltd., expanded a recall of the ARB called losartan, which has been found to be contaminated with a different potential carcinogen called NMBA.(Updates with Italian recall starting in first paragraph.)To contact the reporter on this story: Anna Edney in Washington at aedney@bloomberg.netTo contact the editors responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, Timothy AnnettFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Trovagene's Onvansertib Shows Response in Phase Ib AML Study
    Zacks

    Trovagene's Onvansertib Shows Response in Phase Ib AML Study

    Trovagene (TROV) successfully completes a phase Ib study, evaluating onvansertib in combination with standard-of-care in AML patients. The regimen is well tolerated and safe.

  • CGM Devices Gain Steam, Set New Trend in Diabetes Management
    Zacks

    CGM Devices Gain Steam, Set New Trend in Diabetes Management

    The FDA authorization classifies the new type of CGM devices in class II and subjects these to certain criteria called special controls.

  • Alnylam Focuses on Pipeline Development Amid Competition
    Zacks

    Alnylam Focuses on Pipeline Development Amid Competition

    Alnylam (ALNY) is on track with the development of its pipeline despite stiffening competition.

  • Alnylam Begins Phase III Study on Onpattro for New Indication
    Zacks

    Alnylam Begins Phase III Study on Onpattro for New Indication

    Alnylam (ALNY) starts phase III APOLLO-B study on its lead drug Onpattro for treating transthyretin amyloidosis with cardiomyopathy. Shares rise.

  • Abbott Partners With Sanofi to Upgrade Diabetes Management
    Zacks

    Abbott Partners With Sanofi to Upgrade Diabetes Management

    Abbott (ABT) collaborates with Sanofi to revolutionize diabetes care through technological advancements.

  • Reuters

    Factbox: Britain's insulin providers prepare for Brexit fallout

    With Britain sourcing the vast majority of the insulin needed by its 1 million diabetics from overseas, its biggest providers have had to restructure their supply chains in case a chaotic Brexit disrupts the normal arteries of trade. Below are some of the steps Novo Nordisk, Eli Lilly and Sanofi have taken to prepare for Britain's departure from the European Union on Oct. 31. - All three firms have increased the amount of insulin they are holding inside the country in case a no-deal Brexit leads to customs checks and lengthy delays at Britain's biggest ports of Dover and Folkestone.

  • PR Newswire

    Happify Health and Sanofi Sign Global Agreement to Bring Prescription Digital Mental Health Therapeutics to Individuals with Multiple Sclerosis

    NEW YORK, Sept. 17, 2019 /PRNewswire/ -- Happify Health, a global leader in mental health technology, today announced it signed an agreement with global biopharmaceutical company Sanofi (SNY) to advance the application of digital therapeutics to address key co-morbidities for individuals living with multiple sclerosis (MS), including depression and anxiety. Happify Health will develop a version of its digital platform specifically for people with MS and plans to submit the co-developed digital therapy to the U.S. Food and Drug Administration for clearance as a medical device. "We've been preparing for our entry into prescription digital therapeutics for several years," said Ofer Leidner, co-founder and president of Happify Health.

  • Aimmune's Peanut Allergy Drug Gets FDA Committee's Support
    Zacks

    Aimmune's Peanut Allergy Drug Gets FDA Committee's Support

    Aimmune's (AIMT) peanut allergy drug gets majority of votes from the Advisory Committee of the FDA.

  • Abbott, Sanofi to help diabetes patients with technology team-up
    Yahoo Finance

    Abbott, Sanofi to help diabetes patients with technology team-up

    Abbott and Sanofi announce a new collaboration to help diabetes patients.

  • Market Exclusive

    Market Morning: Johnson Defies Benn, Saudi Oil Black Swan, Golden Toilet Heist

    Mainstream Media Starts Seeing Stark Central Banking Dilemma The mainstream media is starting to catch on to the fact that central banks might be toast, and not the lightly toasted kind that enhances flavor. More like the Cajun kind that turns everything black. Reuters opens an ominous report on the European Central Bank entitled “Draghi's […]The post Market Morning: Johnson Defies Benn, Saudi Oil Black Swan, Golden Toilet Heist appeared first on Market Exclusive.

  • Business Wire

    Hagens Berman: National Class-Action Lawsuit Accuses Sanofi of Concealing Zantac Cancer Risk

    A newly filed class-action lawsuit accuses international drug maker Sanofi of intentionally concealing risks in its popular heartburn medication, Zantac, which has been found to contain a carcinogenic chemical at 26,000 times the FDA-approved limit, according to the lawsuit filed by Hagens Berman. If you have taken Zantac, you may have ingested carcinogens. The lawsuit, filed Sept. 13, 2019, in the U.S. District Court for the Northern District of California accuses Sanofi and Boehringer Ingelheim of knowingly manufacturing and selling over-the-counter Zantac containing a concealed carcinogen to millions of people in the U.S. suffering from heartburn and other gastrointestinal issues, including sour stomach, acid reflux or gastroesophageal reflux disease (GERD).

  • Popular Sanofi Heartburn Drug Could Contain Carcinogens, FDA Says
    Investor's Business Daily

    Popular Sanofi Heartburn Drug Could Contain Carcinogens, FDA Says

    A commonly used heartburn medicine from Sanofi, known as Zantac, could contain cancer-causing substances, the Food and Drug Administration said Friday. Sanofi stock fell a fraction.

  • Glaxo's Asthma Drug Nucala Gets FDA Nod for Pediatric Use
    Zacks

    Glaxo's Asthma Drug Nucala Gets FDA Nod for Pediatric Use

    Glaxo's (GSK) asthma medicine, Nucala gets FDA approval for use in pediatric patient population.

  • TheStreet.com

    FDA Says Sanofi's Zantac Medication Has Impurity That Could Cause Cancer

    The FDA isn't calling for consumers to stop taking heartburn relief medicines with ranitidine 'at this time.'

  • Investing.com

    NewsBreak: Low Levels of Carcinogen Found in Heartburn Drug Zantac

    Investing.com - U.S. and European health officials are investigating big-selling heartburn treatment Zantac and generics of the drug after a carcinogen was discovered in low levels, Bloomberg first reported Friday.

  • J&J's Ponesimod Superior to Aubagio in Relapsing MS Patients
    Zacks

    J&J's Ponesimod Superior to Aubagio in Relapsing MS Patients

    J&J (JNJ) announces superiority of its multiple sclerosis candidate, ponesimod compared to Sanofi's Aubagio in patients with relapsing form of the disease.

  • Woodlands-based pharma co. to receive $260M in drug dispute settlement
    American City Business Journals

    Woodlands-based pharma co. to receive $260M in drug dispute settlement

    In addition to a $260 million payout, the drug dispute settlement returns worldwide development and commercialization rights to Houston-area firm.